Ma­gen­ta's blood can­cer ADC faces two dose-lim­it­ing tox­i­c­i­ties, trig­ger­ing co­hort stop­page

Ma­gen­ta Ther­a­peu­tics has in­formed the FDA of two dose-lim­it­ing tox­i­c­i­ties in the high­est-dose group of its Phase I/II study. No more pa­tients will be dosed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER